1. Home
  2. CTW vs GLSI Comparison

CTW vs GLSI Comparison

Compare CTW & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTW

CTW Cayman Class A Ordinary Shares

N/A

Current Price

$1.91

Market Cap

132.9M

Sector

Technology

ML Signal

N/A

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$22.23

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTW
GLSI
Founded
2013
2006
Country
Japan
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.9M
123.9M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
CTW
GLSI
Price
$1.91
$22.23
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$50.00
AVG Volume (30 Days)
58.4K
805.0K
Earning Date
11-17-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$90,370,793.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$30.87
N/A
Revenue Growth
32.07
N/A
52 Week Low
$1.71
$7.78
52 Week High
$4.88
$30.82

Technical Indicators

Market Signals
Indicator
CTW
GLSI
Relative Strength Index (RSI) N/A 66.20
Support Level N/A $18.54
Resistance Level N/A $25.20
Average True Range (ATR) 0.00 3.94
MACD 0.00 0.55
Stochastic Oscillator 0.00 58.63

Price Performance

Historical Comparison
CTW
GLSI

About CTW CTW Cayman Class A Ordinary Shares

CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: